Search results for "raft"

showing 10 items of 1545 documents

Effects of leflunomide on immune responses and models of inflammation.

1993

Leflunomide is an antiphlogistic and immunomodulating agent that has been shown to be effective in preventing and healing autoimmune disorders and reactions leading to organ graft rejection. From our preliminary clinical data [4], we now have hopes that these effects, observed in experimental animals, can truly be transferred to humans. Although we are far from understanding the mode of action of leflunomide, we are slowly gathering some insight. A good many of the immunosuppressive effects of leflunomide can be attributed to the antagonistic effects it has on responses to many cytokines, most likely through receptor expression and signal transduction (tyrosine kinase inhibition). The inhib…

Graft RejectionReceptor expressionImmunologyDrug Evaluation PreclinicalAutoimmune Diseaseschemistry.chemical_compoundMiceImmune systemMedicineAnimalsHumansLeflunomideInflammationImmunity Cellularbusiness.industryAnti-Inflammatory Agents Non-SteroidalAutoantibodyGeneral MedicineIsoxazolesProtein-Tyrosine KinasesRatsDisease Models AnimalchemistryImmunologyAntibody FormationCytokinesSignal transductionbusinessTyrosine kinaseImmunomodulating AgentHistamineImmunosuppressive AgentsLeflunomidemedicine.drugSpringer seminars in immunopathology
researchProduct

Results of heart retransplantation: subanalysis of the Spanish Heart Transplant Registry

2021

Heart retransplantation (ReHT) is controversial in the current era. The aim of this study was to describe and analyze the results of ReHT in Spain. Methods We performed a retrospective cohort analysis from the Spanish Heart Transplant Registry from 1984 to 2018. Data were collected on donors, recipients, surgical procedure characteristics, immunosuppression, and survival. The main outcome was posttransplant all-cause mortality or need for ReHT. We studied differences in survival according to indication for ReHT, the time interval between transplants and era of ReHT. Results A total of 7592 heart transplants (HT) and 173 (2.3%) ReHT were studied (median age, 52.0 and 55.0 years, respectively…

Graft RejectionReoperationmedicine.medical_specialtyTrasplante cardiacoSurvivalmedicine.medical_treatmentRetrasplante cardiacoEnfermedad cardiovascularCardiac allograft vasculopathyCold Ischemia TimeHeart retransplantation Heart transplant Retrasplante cardiaco Supervivencia Survival Trasplante cardiacoCirugíaInternal medicinemedicineHumansRegistriesTrasplante de corazónBalloon pumpPrimary graft failureRetrospective StudiesMechanical ventilationHeart transplantsSupervivenciabusiness.industryAnálisis de datosImmunosuppressionRetrospective cohort studyGeneral MedicineMiddle AgedSpainHeart retransplantationCardiologyHeart TransplantationHeart transplantbusiness
researchProduct

Organ xenografting between rodents: an evolutionary perspective

1994

Rejection times of heart xenografts in several donor-recipient combinations including the guinea pig, rat, hamster, and mouse are examined in light of the paleontological history of rodents and the resulting phylogenetic distances between taxa. This multidisciplinary review at the molecular, chromosomal and morphological levels suggests that xenograft rejection time is inversely proportional to the time divergence or phylogenetic distance, and that the binomial terminology concordant/discordant does not reflect the amplitude of phylogenetic distances.

Graft RejectionTransplantationPhylogenetic treeXenotransplantationmedicine.medical_treatmentTransplantation HeterologousHamsterZoologyRodentiaBiologyGuinea pigMultidisciplinary reviewPhylogenetic distanceTaxonTransplant surgeryEvolutionary biologymedicineAnimalsHeart TransplantationHumansPhylogenyTransplant International
researchProduct

The effect of ischemia/reperfusion on the kidney graft.

2014

Ischemia/reperfusion injury is an unavoidable companion after kidney transplantation and influences short-term as well as long-term graft outcome. Clinically ischemia/reperfusion injury is associated with delayed graft function, graft rejection, and chronic graft dysfunction. Ischemia/reperfusion affects many regulatory systems at the cellular level as well as in the renal tissue that eventually result in a distinct inflammatory reaction of the kidney graft.Underlying factors include energy metabolism, cellular changes of the mitochondria and cellular membranes, initiation of different forms of cell death-like apoptosis and necrosis together with a recently discovered mixed form termed necr…

Graft RejectionTransplantationmedicine.medical_specialtyKidneyGraft dysfunctionGraft rejectionbusiness.industryT-LymphocytesIschemiamedicine.diseaseKidney TransplantationDelayed Graft FunctionImmunity InnateSurgerysurgical procedures operativemedicine.anatomical_structureImmunityReperfusion InjurymedicineImmunology and AllergyAnimalsHumansbusinessReperfusion injuryKidney transplantationCurrent opinion in organ transplantation
researchProduct

Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients

2013

The introduction of tacrolimus in clinical practice has improved patient survival after organ transplant. However, despite the long use of tacrolimus in clinical practice, the best way to use this agent is still a matter of intense debate. The start of the genomic era has generated new research areas, such as pharmacogenetics, which studies the variability of drug response in relation to the genetic factors involved in the processes responsible for the pharmacokinetics and/or the action mechanism of a drug in the body. This variability seems to be correlated with the presence of genetic polymorphisms. Genotyping is an attractive option especially for the initiation of the dosing of tacrolim…

Graft Rejectionmedicine.medical_specialtyCYP3A5ATP Binding Cassette Transporter Subfamily BCYP3A4Genotypemedicine.medical_treatmentPharmacologyLiver transplantationBioinformaticsOrgan transplantationTacrolimusCalcineurin inhibitorMedicineCytochrome P-450 CYP3AHumansDrug Dosage CalculationsDosingATP Binding Cassette Transporter Subfamily B Member 1Topic HighlightKidney transplantLiver transplantKidney transplantationBiotransformationPolymorphism Geneticbusiness.industryPharmacogeneticGraft SurvivalGastroenterologyABCB1General Medicinemedicine.diseaseKidney TransplantationTacrolimusLiver TransplantationSingle nucleotide polymorphismTransplantationsurgical procedures operativePhenotypeTreatment OutcomePharmacogeneticsTacrolimuSettore BIO/14 - FarmacologiaPersonalized medicinebusinessPharmacogeneticsImmunosuppressive Agents
researchProduct

MicroRNAs in solid organ and vascularized composite allotransplantation: Potential biomarkers for diagnosis and therapeutic use

2020

Abstract Nowadays, solid organ transplantation (SOT) is an established treatment for patients with end-organ dysfunction, which dramatically improves the quality-of-life. Vascularized composite allotransplants (VCAs) including hand and face have been reported worldwide over the last 20 years. However, VCAs, differently to SOT, are life-enhancing instead of life-saving and are not routinely performed due to the risk of immune rejection and the adverse effects of immunosuppression. Over the past decade, although considerable improvements in short-term outcomes after allotransplantation have been registered, these results have not been translated into major progress in long-term allograft acce…

Graft Rejectionmedicine.medical_specialtyImmune rejectionmedicine.medical_treatmentBioinformaticsVascularized Composite AllotransplantationOrgan transplantationRNA interferencemicroRNABiomarker; Immune rejection; Micro-RNAs; Organ transplantation; Tolerance; Vascularized composite allotransplantationsmedicineHumansBiomarker discoveryVascularized composite allotransplantationsImmunosuppression TherapyVascularized Composite AllotransplantationTransplantationOrgan transplantationbusiness.industryMicro-RNAsImmunosuppressionBiomarkerBiomarker (cell)MicroRNAsVascularized composite allotransplantations Micro-RNAs Biomarker Immune rejection Organ transplantation TolerancebusinessToleranceBiomarkersAllotransplantation
researchProduct

Uterine rejection after allogeneic uterus transplantation in the rat is effectively suppressed by tacrolimus

2013

Objective To evaluate the effects of the immunosuppressant tacrolimus on rejection of a transplanted uterus and on uterine expression of markers of inflammation and implantation. Design Experimental study. Setting University laboratory. Animal(s) Female rats. Intervention(s) Uteri from brown Norway rats were transplanted to Lewis rats, receiving either tacrolimus or no treatment. Sham groups underwent either hemihysterectomy or tacrolimus treatment. Main Outcome Measure(s) Gross morphology, histology, density of T-lymphocytes by immunohistochemistry, and mRNA levels of interleukin (IL)-1α, leukemia inhibitory factor (LIF), galectin-1, CD200, IL-15, interferon-inducible protein-10 (IP-10), a…

Graft Rejectionmedicine.medical_specialtyNecrosisGalectin 1UterusHysterectomyTacrolimusAndrologyNecrosisInterleukin-1alphaRats Inbred BNInternal medicineUterus transplantationmedicineAnimalsTransplantation HomologousInflammationbusiness.industryUterusObstetrics and GynecologyInterleukinHistologyOrgan TransplantationTacrolimusRatsChemokine CXCL10Transplantationsurgical procedures operativeEndocrinologymedicine.anatomical_structureReproductive MedicineRats Inbred LewFemalemedicine.symptombusinessLeukemia inhibitory factorBiomarkersImmunosuppressive AgentsFertility and Sterility
researchProduct

Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies

2014

The highly variable pharmacokinetics of tacrolimus can hamper the optimal management of kidney transplant patients. This variability has been attributed to the genetic polymorphism of CYP3A5 6986A>G, but the evidence is not clear. We conducted a meta-analysis of studies evaluating the effect of CYP3A5 polymorphism on kidney transplant recipients with tacrolimus plasma concentration divided by daily dose per body weight (C/D) and clinical outcomes. We searched in MEDLINE and EMBASE. We found evidence suggesting a significantly lower C/D among CYP3A5*1 allele carriers compared with carriers of the CYP3A5*3/*3 genotype at weeks 1 and 2, and months 1, 3, 6 and 12. We demonstrated that the expre…

Graft Rejectionmedicine.medical_specialtyPharmacologyGastroenterologyKidney transplantTacrolimusPharmacokineticsInternal medicineGenotypeGeneticsmedicineCytochrome P-450 CYP3AHumansAlleleCYP3A5Pharmacologybusiness.industryKidney TransplantationTransplant RecipientsTacrolimusObservational Studies as Topicsurgical procedures operativeMeta-analysisMolecular MedicineObservational studybusinessImmunosuppressive Agents
researchProduct

Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes.

2009

To examine the impact of steroid withdrawal from the immunosuppression protocols in liver transplantation. The electronic databases Medline, Embase, Pubmed and the Cochrane Library were searched. Meta-analysis pooled the effects of outcomes of a total of 2590 patients enrolled into 21 randomized controlled trials (RCTs), using classic and modern meta-analytic methods. Meta-analysis of RCTs addressing patients transplanted for any indication showed no differences between corticosteroid-free immunosuppression and steroid-based protocols in most of the analyzed outcomes. More importantly, steroid-free cohorts appeared to benefit in terms of de novo diabetes mellitus development [R.R = 1.86 (1.…

Graft Rejectionmedicine.medical_specialtymedicine.medical_treatmentCochrane LibraryLiver transplantationlaw.inventionRandomized controlled triallawAdrenal Cortex HormonesInternal medicinemedicineHumansRandomized Controlled Trials as TopicHepatitisImmunosuppression TherapyTransplantationEvidence-Based Medicinebusiness.industryGraft SurvivalImmunosuppressionHepatitis Cmedicine.diseaseHepatitis CSurgeryLiver TransplantationTransplantationTreatment OutcomeMeta-analysisRegression AnalysisbusinessImmunosuppressive AgentsTransplant international : official journal of the European Society for Organ Transplantation
researchProduct

Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients

2016

Appropriate post-transplant immunosuppressive regimens that avoid acute rejection, while reducing risk of viral reactivation, have been sought, but remain a chimera. Recent evidence suggesting potential regulatory and antiviral effects of mammalian target of rapamycin inhibitors (mTORi) is of great interest. Although the concept of an immunosuppressive drug with antiviral properties is not new, little effort has been made to put the evidence together to assess the management of immunosuppressive therapy in the presence of a viral infection. This review was developed to gather the evidence on antiviral activity of the mTORi against the viruses that most commonly reactivate in adult solid org…

Graft Rejectionmedicine.medical_specialtymedicine.medical_treatmentHepatitis C virus030230 surgerymedicine.disease_causeAntiviral AgentsOrgan transplantationVirus03 medical and health sciencesChimera (genetics)0302 clinical medicinemedicineHumansImmunosuppression TherapyTransplantationEverolimusbusiness.industryTOR Serine-Threonine Kinasesvirus diseasesImmunosuppressionOrgan TransplantationTransplant RecipientsInfectious DiseasesImmunosuppressive drugVirus DiseasesSirolimusImmunology030211 gastroenterology & hepatologybusinessImmunosuppressive Agentsmedicine.drugTransplant Infectious Disease
researchProduct